130 related articles for article (PubMed ID: 26287187)
21. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.
Yun C; Gang L; Rongmin G; Xu W; Xuezhi M; Huanqiu C
Mol Carcinog; 2015 Dec; 54(12):1700-9. PubMed ID: 25400108
[TBL] [Abstract][Full Text] [Related]
22. VERO stable cell lines expressing full-length human epidermal growth factor receptors 2 and 3: platforms for subtractive phage display.
Hedayatizadeh-Omran A; Valadan R; Rafiei A; Tehrani M; Alizadeh-Navaei R
DNA Cell Biol; 2015 Sep; 34(9):573-8. PubMed ID: 26121156
[TBL] [Abstract][Full Text] [Related]
23. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
Liu S; Wang H; Zhang L; Tang C; Jones L; Ye H; Ban L; Wang A; Liu Z; Lou F; Zhang D; Sun H; Dong H; Zhang G; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Huang XF; Chen SY; Zhou T
Hum Genomics; 2015 Feb; 9(1):2. PubMed ID: 25757876
[TBL] [Abstract][Full Text] [Related]
24. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
[TBL] [Abstract][Full Text] [Related]
25. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
26. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Berg D; Wolff C; Malinowsky K; Tran K; Walch A; Bronger H; Schuster T; Höfler H; Becker KF
J Cell Physiol; 2012 Jan; 227(1):204-12. PubMed ID: 21391216
[TBL] [Abstract][Full Text] [Related]
27. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
28. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
30. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
[TBL] [Abstract][Full Text] [Related]
31. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
32. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
33. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
35. Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas.
Oikawa M; Miki Y; Shimizu Y; Kumamoto H
J Oral Pathol Med; 2013 May; 42(5):424-34. PubMed ID: 23278525
[TBL] [Abstract][Full Text] [Related]
36. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
[TBL] [Abstract][Full Text] [Related]
37. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
38. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.
De Boeck A; Pauwels P; Hensen K; Rummens JL; Westbroek W; Hendrix A; Maynard D; Denys H; Lambein K; Braems G; Gespach C; Bracke M; De Wever O
Gut; 2013 Apr; 62(4):550-60. PubMed ID: 22535374
[TBL] [Abstract][Full Text] [Related]
40. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
